[EN] ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'HORMONE DE MELANO-CONCENTRATION
申请人:——
公开号:WO2003106452A3
公开(公告)日:2004-04-08
Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 Antagonists: Assessment of Potency, Efficacy, and Cardiovascular Safety
作者:John K. Lynch、Jennifer C. Freeman、Andrew S. Judd、Rajesh Iyengar、Mathew Mulhern、Gang Zhao、James J. Napier、Dariusz Wodka、Sevan Brodjian、Brian D. Dayton、Doug Falls、Christopher Ogiela、Regina M. Reilly、Thomas J. Campbell、James S. Polakowski、Lisa Hernandez、Kennan C. Marsh、Robin Shapiro、Victoria Knourek-Segel、Brian Droz、Eugene Bush、Michael Brune、Lee C. Preusser、Ryan M. Fryer、Glenn A. Reinhart、Kathryn Houseman、Gilbert Diaz、Ann Mikhail、James T. Limberis、Hing L. Sham、Christine A. Collins、Philip R. Kym
DOI:10.1021/jm060683e
日期:2006.11.1
Evaluation of multiple structurally distinct series of melanin concentrating hormone receptor 1 antagonists in an anesthetized rat cardiovascualar assay led to the identification of a chromone-2-carboxamide series as having excellent safety against the chosen cardiovascular endpoints at high drug concentrations in the plasma and brain. Optimization of this series led to considerable improvements in affinity, functional potency, and pharmacokinetic profile. This led to the identification of a 7-fluorochromone-2-carboxamide (22) that was orally efficacious in a diet-induced obese mouse model, retained a favorable cardiovascular profile in rat, and demonstrated dramatic improvement in effects on mean arterial pressure in our dog cardiovascular model compared to other series reported by our group. However, this analogue also led to prolongation of the QT interval in the dog that was linked to affinity for hERG channel and unexpectedly potent functional blockade of this ion channel.
Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
申请人:Lynch K. John
公开号:US20050209274A1
公开(公告)日:2005-09-22
The present invention is directed to compounds of formula (I),
which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
Antagonists of melanin concentrating hormone receptor
申请人:Millennium Pharmaceuticals, Inc.
公开号:US20040106645A1
公开(公告)日:2004-06-03
This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I:
1
where m is zero or one, n is zero to two, Y is oxygen or —N(R
9
)—, R
1
, R
2
, R
3
, R
4
, R
5
, R
9
and Ring A are defined in the specification. Coumarin and quinolone compounds where R
1
and R
2
together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.
这项发明提供了一些与黑色素浓集激素受体-1 (MCH-R1) 相对抗的化合物。这些化合物由公式 I 表示:其中 m 为零或一,n 为零至二,Y 为氧或 —N(R9)—,R1、R2、R3、R4、R5、R9 和环 A 在说明书中有定义。偏好使用 R1 和 R2 结合形成融合苯环的香豆素和喹啉类化合物。该发明还提供了公式 VI 的化合物,其中香豆素基团被喹嗪酮环替换。这些化合物可用于治疗与 MCH-R1 相关的疾病,特别是超重症,包括肥胖症。